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ABSTRACT
Objectives. Selective cyclooxygenase (COX)-2 inhibitors are effective analgesic and anti-inﬂammatory agents with
improved gastrointestinal safety and tolerability compared with traditional NSAIDs. However, data from long-term,
placebo-controlled studies have shown an increased risk of thrombotic cardiovascular (CV) events for COX-2
inhibitors. Changes in levels of CV biomarkers are potentially useful surrogate measures of pathologic changes
associated with CV risk.
Methods. We randomized 433 patients with osteoarthritis to etoricoxib 90 mg once daily, celecoxib 200 mg twice
daily, ibuprofen 800 mg three times daily, or placebo for 12 weeks. The hypothesis was that etoricoxib would be
non-inferior or superior to placebo in effect on C-reactive protein (CRP), LDL-cholesterol, homocysteine, and
ﬁbrinogen.
Results. Relative to placebo, etoricoxib was noninferior for effect on CRP (decreased 7.8% vs. placebo; 97.5% CI
of the difference: -30.5, 22.4), LDL-C (-4.0% vs. placebo; 97.5% CI: -10.6, 3.2), homocysteine (-3.9% vs. placebo;
97.5% CI: -11.6, 4.6), and ﬁbrinogen (-3.7% vs. placebo; 97.5% CI: -9.4, 2.3). Etoricoxib was not different from
placebo, celecoxib, or ibuprofen for any biomarker.
Conclusion. Etoricoxib was comparable to placebo, celecoxib, and ibuprofen for effects on the CV risk markers
measured.
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ecent data suggest that long-term use of both
traditional NSAIDs and cyclooxygenase-2
(COX-2) selective NSAIDs may increase cardio-
vascular (CV) risk compared with placebo [1–4].
Although several mechanistic hypotheses have
been explored [5], the reason(s) for this increased
risk still remains unclear and the subject of further
investigation.
Etoricoxib is a selective COX-2 inhibitor used
for the treatment of pain and inﬂammation, and is
associated with a reduced risk of gastrointestinal
clinical events and intolerability compared to tra-
ditional NSAIDs [6–9]. The recently completed
multinational etoricoxib and diclofenac arthritis
long-term (MEDAL) Program provided a direct
and formal non-inferiority comparison of CV risk
with the most widely used traditional NSAID
diclofenac [10]. In the MEDAL Program, the risk
of CV events associated with chronic, long-term
administration of etoricoxib 60 or 90 mg daily, and
This work was performed and ﬁnanced by Merck Research
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rheumatoid arthritis patients were shown not to be
different from one another in arthritis patients
with a variety of baseline risk factors [11].
We chose to examine the effects of etoricoxib
and comparator NSAIDs on four well-
characterized biomarkers of cardiac risk. Low-
density-lipoprotein cholesterol (LDL-C) [12–14]
is a well established marker of cardiac risk, and
homocysteine [15,16], ﬁbrinogen [17–19], and
C-reactive protein [20–23] (CRP) are considered
potential markers [24,25]. These biomarkers rep-
resent different processes implicated in the genesis
of clinical CV disease—atherosclerosis, thrombo-
sis, and inﬂammation. Elevation in the levels of
each of these has been shown to be associated with
CV risk [24,25]. In this study, etoricoxib, the
COX-2 selective inhibitor celecoxib, and tradi-
tional NSAID ibuprofen were tested at their
maximum recommended chronic doses in patients
with osteoarthritis. Etoricoxib 90 mg/day is rec-
ommended for chronic symptomatic treatment of
rheumatoid arthritis. Celecoxib 400 mg/day is the
approved dosage for osteoarthritis and the recom-
mended dosage for rheumatoid arthritis. Ibupro-
fen 2,400 mg/day is within the range of the
recommended daily dose for osteoarthritis (1,200–
3,200 mg/day).
Methods
Etoricoxib protocol 065 was a 12-week, random-
ized, parallel-group, double-blind, placebo-
controlled trial performed at 60 centers in the
United States (see Appendix for list of investiga-
tors). The study group consisted of men and
women aged 40 years old who had been diag-
nosed with osteoarthritis and treated with
NSAIDS and/or COX-2 inhibitors within the pre-
vious year. Patients were instructed not to take
non-study NSAIDs/COX-2 inhibitors and aspirin
during the study. Exclusion criteria included
inﬂammatory arthritis or any other systemic
inﬂammatory disease, gastrointestinal malabsorp-
tion, evidence of signiﬁcantly impaired renal func-
tion (creatinine clearance <30 mL/min), moderate
to severe congestive heart failure (NYHA Class III
or IV), history of atherosclerotic cardiac disease,
uncontrolled hypertension, history of cerebrovas-
cular disease, a bleeding diathesis, and active
hepatic disease. Patients were also excluded if
they were taking oral contraceptives or hormone
replacement therapy, or were pregnant or nursing.
Women of childbearing potential had to have a
negative serum b-hCG level at screening and were
instructed to use contraception measures. All par-
ticipants provided written informed consent. The
study was approved by a centralized institutional
review board for the majority of the study sites and
by the speciﬁc review board for the institution at
the remaining sites. The study was conducted
according to the principles of the Declaration of
Helsinki.
Patients who had taken an NSAID or COX-2
inhibitor any time within the 2 weeks prior to
screening (visit 1) underwent a 14-day washout,
returnedforevaluations(visit2),andreturnedafter
one week to be randomized to treatment (visit 3,
baseline).Allotherpatientsreturnedoneweekafter
screening to be randomized to treatment. After
clinical exams were complete, all eligible patients
were randomized according to a computer-
generated, sponsor-supplied random allocation
schedule in a 1:1:1:1 ratio to one of the following
four treatments: etoricoxib 90 mg once daily, cele-
coxib 200 mg twice daily, ibuprofen 800 mg three
times daily, or placebo. In addition, they received
matching placebos for the other three treatments.
Patients were assigned an allocation number in
consecutive, ascending order from the block of
allocationsthateachspeciﬁcsitereceived.Blinding
was maintained using bottles labeled with the
patients’allocationnumber.Compliancewasdeter-
mined from a pill count at each study visit. If more
than 20% of the doses for an individual bottle was
missed between two consecutive visits, the patient
was considered noncompliant.
Patients had fasting blood sampling at screen-
ing, randomization (baseline) and 6 and 12 weeks
(3 months). Biomarkers were analyzed by PPD
Global Central Labs (Highland Heights, Ken-
tucky). This laboratory maintains continuous
certiﬁcation by the CDC lipids program to ensure
assay accuracy, and participates in the CAP
Proﬁciency program for CRP, ﬁbrinogen, and
homocysteine. CRP was measured in serum or
plasma using a high-sensitivity automated assay on
the Behring Nephelometer II and mouse mono-
clonal CRP antibodies coated on polystyrene
particles. The assay was linear in the range 0.04–
2,500 mg/L. For the measurement of LDL-C
(beta-quant), plasma was subjected to ultracen-
trifugation, and the fractions were analyzed on a
Hitachi 747 Chemistry analyzer. The range of
linearity for LDL-C was 3–1,000 mg/dL. Homo-
cysteine was quantitated in plasma or serum via
isocratic high-pressure liquid chromatography.
The internal standard was L-homocystine, a dimer
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in the range 1.0–80 mM. Plasma ﬁbrinogen
was measured via immunoassay on a Behring
Nephelometer using rabbit anti-human antisera.
The range of linearity was 60–976 mg/dL. Each
biomarker assay was run with low and high quality
control samples. The precision (percent coefﬁ-
cient of variation) of the quality control samples
was in the range of 3.9–4.6% for the CRP assay,
3.1–3.3% for LDL-C (beta quant), 3.6–5.8% for
homocysteine, and 3.0–4.6% for ﬁbrinogen.
Physical exam, electrocardiogram, and com-
plete fasting laboratory tests were performed
during screening. Vital signs and body weight were
evaluated at screening, randomization, week 6, and
week 12. Adverse events were collected through-
out the study and monitored from screening
through 14 days after the ﬁnal dose of study drug.
At each visit, patients were questioned as to
whether any adverse experience had occurred
since the prior visit. Investigators evaluated
adverse experiences with regard to severity (i.e.,
mild, moderate, or severe) and the likelihood of a
relation to study medication. All adverse experi-
ences were reported to the study sponsor and
adverse experiences deemed to be serious (i.e.,
resulted in death, prolonged an existing hospital-
ization, lead to disability, or caused a birth defect
in offspring of patients) were reported within 24
hours. All potential thrombotic CV events and
deaths, regardless of cause, were adjudicated by an
independent expert Case Review Committee (see
Appendix) that was blinded to treatment assign-
ment, as were upper gastrointestinal events (per-
forations, ulcers, bleeds) according to previously
described criteria [26].
The clinical supplies were packaged according
to the allocation schedule and blinded to the inves-
tigator, patient, and sponsor representatives. The
ofﬁcial clinical database was not unblinded until
medical and scientiﬁc review had been completed,
protocol violators had been identiﬁed, per-
protocol and modiﬁed-intention-to-treat popula-
tions had been deﬁned, and the database had been
declared complete.
Data Analysis
The primary statistical analysis used the per-
protocol population, according to clinical trial
guidelines [27–29]. The per-protocol population
consisted of patients who had valid data at ran-
domization, had at least one post-randomization
visit, did not take prohibited medication, had
80% compliance with study drug, and had their
ﬁnal biomarker sample drawn within the estab-
lished window for month 3 (day 84  14 days).
Supportive analyses were based on the modiﬁed-
intention-to-treat population, which consisted of
patients with valid data at randomization and valid
data from the month 3 visit (or week 6 visit for the
week 6 analysis), regardless of whether they devi-
ated from the protocol. Analyses of clinical and
laboratory adverse experiences used data from all
randomized patients.
Two primary hypotheses were tested hierarchi-
cally: etoricoxib 90 mg once daily would be (i)
non-inferior to placebo in its effect on mean
change from baseline for each biomarker after 3
months of treatment; and (ii) non-inferior to cele-
coxib 200 mg twice daily in its effect on mean
change from baseline for each biomarker after 3
months of treatment. To maintain a 5% type I
error rate for the overall hypothesis, each compari-
son (i.e., etoricoxib vs. placebo and etoricoxib vs.
celecoxib) was conducted at the 2.5% level. There-
fore, 97.5% CIs were provided. For etoricoxib to
be declared non-inferior to placebo, the upper
bound of the 97.5% CI for the relative difference
in percentage points had to satisfy the following
joint non-inferiority criteria: <20% for LDL-C,
ﬁbrinogen, and homocysteine; and <80% for CRP.
These margins were based on variability in the
markers, as observed in prospective epidemiologi-
cal studies [30–32]. From these epidemiological
data, the standard deviations for LDL, homocys-
teine and ﬁbrinogen after log-transformation were
comparable at ~0.28; it is greater for CRP at 0.98.
The noninferiority bounds were chosen to make
sure that we would have comparable power for
each biomarker. They each also roughly corre-
sponded to a cardiovascular risk difference at
~25%. If etoricoxib were found to be non-inferior
to placebo, then further testing was to be con-
ducted to determine superiority to placebo, and
only non-inferiority testing (and no superiority
testing) was to be conducted for the comparison
between etoricoxib and celecoxib. If etoricoxib did
not meet non-inferiority criteria compared to
placebo, then etoricoxib would be further com-
pared with celecoxib using the same criteria. If
etoricoxib was non-inferior to celecoxib, then the
second primary hypothesis was considered to have
been met. A secondary hypothesis was that etori-
coxib would be non-inferior to ibuprofen: for
etoricoxib to be declared non-inferior, the upper
bounds of the four (2-sided) 95% CIs for the
relative difference had to meet the same non-
inferiority margins as for the primary hypothesis
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and 80% for CRP). The overall type I error rate
was 5% (two-sided) for the primary hypothesis.
This was achieved by adjusting the type I error rate
for each of the two primary comparisons to 2.5%
(two-sided). Within each comparison, all bio-
markers must have met the prespeciﬁed criteria.
With this conservative approach, which can only
decrease the signiﬁcance level, no further multi-
plicity adjustment was required. For superiority
testing, the overall type I error rate was 5% (two-
sided). Because the superiority hypothesis was
nested within the non-inferiority hypothesis, no
extra multiplicity adjustment was needed for the
duality of the testing.
The analyses used standard longitudinal data
analysis techniques suited for repeated measures.
For each biomarker, log-transformed levels were
ﬁt to a mixed-effects model. The mean difference
in change from baseline (randomization) at month
3 between etoricoxib and the comparator (etori-
coxib minus comparator), along with a per-
protocol, multiplicity-adjusted, two-sided 97.5%
CI were calculated using the log-transformed data.
They were back-transformed exponentially to
obtain their corresponding relative differences and
97.5% CIs in the raw scale.
The study was powered to enroll enough
patients to have 75 patients per group in the per-
protocol population, such that the probabilities to
meet the individual non-inferiority criteria were
96% for LDL-C, 96% for homocysteine, 97% for
ﬁbrinogen, and 93% for CRP. Assuming the four
biomarkers are independent of each other, the
overall power to demonstrate non-inferiority of
etoricoxib to placebo on all four markers was
conservatively estimated to be 83%. The power
analysis was performed before the study and was
pre-speciﬁed in the study protocol. No interim
analyses were conducted. Analysis of clinical
adverse experiences and clinical safety were based
on all patients randomized.
Prespeciﬁed subgroup analyses were conducted
according to gender, age (> or median), history
of diabetes, history of hypertension, current
tobacco use, and 10-year Framingham (LDL-
based) coronary heart disease risk score [33] (> or
median) to further explore the comparison
between etoricoxib and placebo.
A pre-speciﬁed exploratory analysis was con-
ducted to project the relative risk of a major
adverse CV event between etoricoxib and each
comparator at month 3 for the per-protocol popu-
lation. The analysis was conducted using the levels
of the individual biomarkers and the associated
cardiac risk reported in the literature [30–32,34],
along with the observed correlations among the
biomarkers from this study. To account for the
projected impact of all four markers on the cumu-
lative risk in each treatment group, a formula was
developed from the incremental risks associated
with incrementally higher levels of the biomarker,
as reported in the literature. The basic statistical
idea is illustrated in the following example. Con-
sider two correlated biomarkers with a correlation
of q. Suppose that historical data show that cardiac
risk increases 1% if the level of either biomarker
increases by one unit. Then, by the statistical
methods used in this study, the projected cardiac
risk would increase by 2/(1 +q )% if the levels of
both biomarkers simultaneously increase by one
unit.
Results
The study was conducted from September 30,
2002 to July 4, 2003. A total of 54 sites randomized
433 patients, 299 of whom met the criteria for the
per-protocol analysis (Figure 1). Reasons for study
drug discontinuation were similar across the four
treatment groups.
Baseline demographics and vital signs were
similar across the four treatment groups (Table 1).
Additionally, baseline demographics for patients
included in the primary per-protocol analysis were
similar to baseline demographics for all patients
randomized in the study. Arithmetic mean CRP
values ranged from 4.6 mg/L to 6.0 mg/L at ran-
domization, with the etoricoxib group having the
lowest mean value and the celecoxib group having
the highest. CV biomarker values at randomiza-
tion were otherwise similar across treatment
groups (Table 2). For patients who underwent a
washout, comparison of biomarker values between
visits 2 and 3 showed that all biomarkers appeared
to have achieved a steady state, suggesting that any
effect of prior treatment with NSAIDs or COX-2
inhibitors on these markers had dissipated during
the washout period.
Figure 2 shows the geometric mean values of
the biomarkers at randomization, week 6, and
month 3 across the treatment groups. In the ibu-
profen group, the level of homocysteine increased,
and the other biomarkers decreased. Table 2 shows
mean biomarker measurements at randomization
and at month 3; Table 3 shows the results of the
between-group comparisons of mean change. At
month 3, etoricoxib was non-inferior to placebo in
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analysis (Table 3), satisfying the primary hypoth-
esis. The upper bounds of the CIs for the relative
differences for the comparisons between etori-
coxib and placebo fell well below the prespeciﬁed
non-inferiority margin of 80% for CRP and below
20% for ﬁbrinogen, LDL-C, and homocysteine.
The effects of etoricoxib on all four biomarkers
were non-inferior to those observed for both cele-
coxib and ibuprofen (Table 3). Analyses of the
modiﬁed-intention-to-treat population showed
similar results (data not shown). In the per-
protocol population, the month 3 results were
generally in agreement with the week 6 results,
except that for the etoricoxib-vs-placebo compari-
son, the relative difference (in raw scale) between
the groups for CRP was greater at week 6 than at
month 3 (-18.1% at week 6 vs. -7.8% at month 3),
and for the etoricoxib-vs-celecoxib comparison,
the relative difference in CRP was smaller at week
6+ than at month 3 (1.8% at week 6 vs. 23.1% at
month 3).
Subgroup Analyses
Subgroup exploratory analyses of the etoricoxib-
vs-placebo comparison in the per-protocol popu-
lation at month 3 showed results generally
consistent with the primary analysis. The numbers
of diabetic patients or current tobacco users were
small in each group. With the caveat that the large
Figure 1 Patient accounting. *Includes lack of efficacy, protocol deviation, lost to follow-up, moved, withdrew consent, and
miscellaneous reasons. †Data were out of day range because data were collected outside of the protocol deﬁned window
(14 days) for pre-speciﬁed biomarker analysis time points.
Table 1 Baseline patient characteristics
Placebo (N = 111) Etoricoxib (N = 108) Celecoxib (N = 107) Ibuprofen (N = 107)
Mean age (SD) (years) 57.8 (10.1) 59.3 (10.6) 59.3 (10.3) 56.8 (10.2)
Sex [n, (%)]
Women 75 (67.6) 68 (63.0) 64 (59.8) 62 (57.9)
Current tobacco user
[n, (%)]
19 (17.1) 14 (13.0) 11 (10.3) 18 (16.8)
History of [n, (%)]
Diabetes 6 (5.4) 4 (3.7) 4 (3.7) 3 (2.8)
Hypertension 48 (43.2) 48 (44.4) 39 (36.4) 43 (40.2)
Hypercholesterolemia 20 (18.0) 19 (17.6) 18 (16.8) 20 (18.7)
Framingham Risk Score
>Median (6) [n, (%)]
39 (35.1) 42 (38.9) 44 (41.1) 41 (38.3)
8 Cannon et al.
Arch Drug Info 2008;1:4–13number of tests could yield some signiﬁcant results
by chance alone, the results showed that certain
biomarkers decreased signiﬁcantly after etoricoxib
treatment compared with placebo in some sub-
groups. In particular, among current tobacco
users, CRP in the etoricoxib group decreased
signiﬁcantly below placebo (-46.3% vs. placebo,
95% CI of the relative difference between groups:
-65.2%, -17.2%). Also in the etoricoxib group,
CRP decreased 50.8% (95% CI: -81.7, 32.5)
Table 2 Change in biomarker measurements and select vital signs from randomization to week 12 for patients in the
per-protocol population
Placebo Etoricoxib Celecoxib Ibuprofen
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Measurements of Biomarkers Throughout the Study Duration
CRP (mg/L)
Randomization 111 5.4 (6.0) 108 4.6 (6.1) 107 6.0 (6.9) 106 5.2 (5.8)
Week 12 70 5.2 (6.1) 72 4.0 (4.6) 76 4.6 (5.3) 79 4.4 (5.4)
LDL-C (mg/dL)
Randomization 110 127.2 (37.6) 108 121.2 (28.7) 107 131.1 (34.8) 105 124.8 (30.9)
Week 12 69 123.2 (29.5) 72 115.5 (29.2) 76 127.7 (34.4) 79 124.2 (30.9)
Homocysteine (mmol/L)
Randomization 111 9.0 (3.0) 107 8.9 (3.0) 107 9.6 (9.1) 107 9.2 (2.6)
Week 12 71 8.9 (2.7) 72 8.8 (3.2) 76 8.6 (2.4) 79 9.3 (2.9)
Fibrinogen (mg/dL)
Randomization 110 418.5 (81.7) 107 409.8 (84.5) 107 420.6 (86.7) 106 410.3 (82.7)
Week 12 71 413.0 (85.3) 73 388.1 (87.8) 76 396.6 (86.1) 78 386.6 (74.8)
Measurements of Blood Pressure and Body Weight Throughout the Study Duration
Systolic Blood Pressure
Randomization 67 125.5 (31.1) 69 126.7 (14.2) 63 128.3 (13.0) 73 127.1 (14.4)
Week 12 67 126.7 (14.4) 69 130 (14.9) 63 131.8 (14.4) 73 127.8 (16.2)
Diastolic Blood Pressure
Randomization 67 78.3 (7.7) 69 77.2 (7.1) 63 77.3 (7.0) 73 79.2 (8.0)
Week 12 67 78.9 (9.0) 69 78.3 (9.2) 63 78.3 (7.9) 73 77.1 (8.2)
Weight (lb)
Randomization 67 186.3 (43.2) 69 188.9 (47.1) 63 205.5 (44.8) 71 186.2 (36.4)
Week 12 67 186.6 (43.0) 69 190.8 (47.6) 63 205.4 (44.3) 71 188.9 (37.2)
Figure 2 Geometric mean biomar-
ker measurements across treatment
groups in the per-protocol population.
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(95% CI: -55.0, 3.1) below placebo in individuals
with higher than median Framingham risk scores;
while these treatment differences were notewor-
thy, they did not reach statistical signiﬁcance. No
biomarkers increased signiﬁcantly after etoricoxib
compared with placebo in the subgroup analyses.
Tolerability
The percentages of patients with at least one clini-
cal adverse experience, with clinical adverse expe-
riences deemed by the investigator as being
possibly related to study drug, and who discontin-
ued due to such drug-related adverse experiences
were lowest in the placebo group and generally
similar across the active treatment groups
(Table 4). The incidence of patients who discon-
tinued due to any clinical adverse experience was
similar across all groups.
The three nonfatal potential investigator-
reported thrombotic CV events that were reported
in this trial were adjudicated by an external com-
mittee as part of an established adjudication
process for all randomized clinical trials of etori-
Table 3 Difference between etoricoxib and comparators in change in biomarker concentrations from randomization at
month 3
Relative difference (Etoricoxib minus
Comparator) [% (CI)
†]
Upper bound of CI meets
non-inferiority criterion?
‡





CRP -7.8 (-30.5, 22.4) Yes 0.52
LDL-C -4.0 (-10.6, 3.2) Yes 0.20
Homocysteine -3.9 (-11.6, 4.6) Yes 0.30
Fibrinogen -3.7 (-9.4, 2.3) Yes 0.16
Celecoxib
CRP 23.1 (-6.8, 62.7) Yes —
LDL-C -1.4 (-7.4, 4.9) Yes —
Homocysteine -0.4 (-8.9, 9.0) Yes —
Fibrinogen 2.5 (-3.6, 9.0) Yes —
Ibuprofen
CRP 14.0 (-10.1, 44.6) Yes —
LDL-C -2.9 (-8.0, 2.6) Yes —
Homocysteine -3.0 (-10.5, 5.2) Yes —
Fibrinogen 1.0 (-3.9, 6.3) Yes —
†CI was 97.5% for etoricoxib vs. placebo and etoricoxib vs. celecoxib, and 95% for etoricoxib vs. ibuprofen.
‡Test whether upper bound of CI for relative difference is less than non-inferiority margin (i.e., <80% for CRP and <20% for LCL-C, homocysteine, and ﬁbrinogen).
§Applicable only for the etoricoxib-vs-placebo comparison and only if etoricoxib was shown to be non-inferior to placebo.
¶Longitudinal analysis with repeated measures in a per-protocol population. Mixed model included factors for treatment, visit, treatment-by-visit interaction, gender,
current tobacco use, diabetes, hypertension, age category (> or median), and Framingham risk score as ﬁxed effects using an unstructured covariance matrix.
















Clinical Adverse Experiences (AEs)
1 AE 40 (36.0) 50 (46.3) 45 (42.1) 45 (42.1)
1 Drug-related AE
† 13 (11.7) 20 (18.5) 15 (14.0) 20 (18.7)
1 Serious AE 0 (0.0) 1 (0.9) 4 (3.7) 2 (1.9)
Discontinued due to an AE 8 (7.2) 12 (11.1) 11 (10.3) 11 (10.3)
Gastrointestinal (GI) Nuisance Symptoms
‡
GI Symptom AEs 2 (1.8) 7 (6.5) 4 (3.7) 6 (5.6)
Discontinuations 0 (0.0) 2 (1.9) 0 (0.0) 2 (1.9)
Renovascular AEs
Lower Extremity Edema 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Discontinuations 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Congestive Heart Failure 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Hypertension
§ 1 (0.9) 4 (3.7) 1 (0.9) 4 (3.7)
Discontinuations 0 (0.0) 2 (1.9) 0 (0.0) 0 (0.0)
†Determined by the investigator to be possibly, probably or deﬁnitely drug related.
‡Includes abdominal pain, abdominal discomfort, acid reﬂux, dyspepsia, epigastric discomfort, heartburn, nausea and vomiting.
§Hypertension was diagnosed by individual investigators; a formal set of parameters was not provided.
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events was conﬁrmed, an acute myocardial infarc-
tion in a patient in the celecoxib group. The adju-
dication committee determined that there was not
enough information for the other two events to
conﬁrm them as thrombotic CV events; these
events included a trafﬁc accident that lead to death
(this patient was not randomized to study medica-
tion) and a neurological disorder in a patient
receiving etoricoxib. There were no signiﬁcant
upper gastrointestinal clinical adverse experiences
(perforations, ulcers, or upper gastrointestinal
bleeding). With regard to prespeciﬁed adverse
experiences of special interest (i.e., digestive and
renovascular), rates of these adverse experiences
and discontinuations due to these experiences
were generally similar across groups (Table 3).
There were no deaths among randomized patients
in this study.
Discussion
Both COX-2 selective inhibitors and traditional
NSAIDs, with the exception of high-dose
naproxen, have been associated with an increased
risk of thrombotic CV events. The mechanism by
which these therapeutic agents increase this risk is
currently unknown although the inhibition of
PGE2 and prostacyclin, a prostanoid that effects
mediators associated with platelet activation,
hypertension, and atherogenesis, has been sug-
gested as an explanation [35]. The current study
was conducted in order to investigate whether
other factors associated with increased CV risk
could be related to the increased CV risk of these
agents. We investigated the effect of etoricoxib on
four biomarkers of CV risk, i.e., CRP, LDL-C,
homocysteine, and ﬁbrinogen, implicated in the
genesis of clinical CV disease with roles in athero-
sclerosis, thrombosis, and inﬂammation [24].
Treatment with etoricoxib 90 mg for three
months in patients with osteoarthritis was non-
inferior to placebo, celecoxib, and ibuprofen with
respect to its effects on all four biomarkers. More-
over, treatment with etoricoxib 90 mg for up to 3
months did not elevate the levels of any of the
biomarkers studied. These ﬁndings, do not offer
any alternative hypotheses for the increased risk
of CV events compared to placebo observed
with COX-2 selective inhibitors and traditional
NSAIDs beyond those that have been most
studied [35].
While each of the biomarkers evaluated in this
study has been shown to predict CV risk, it is
important to note that they should not be con-
sidered a substitute for clinical outcomes. The
current study was not of sufﬁcient duration or
adequately powered to draw any conclusions about
the effects of etoricoxib, celecoxib, or ibuprofen on
CV clinical outcomes. Data from the MEDAL
Program, a CV clinical outcomes program that
evaluated etoricoxib and the traditional NSAID
diclofenac, has recently become available [36].
Additionally, other outcomes programs that aim to
evaluate CV clinical outcomes of other agents have
been initiated [37].
In summary, the effects of etoricoxib on CRP,
LDL-C, homocysteine, and ﬁbrinogen were com-
parable with those of placebo, celecoxib, and ibu-
profen in patients with osteoarthritis. While an
absence of an adverse effect of etoricoxib on estab-
lished CV biomarkers over 3 months cannot be
interpreted as evidence of absence of a clinical CV
risk, the data from the current study provide
important information about the effects of selec-
tive COX-2 inhibition on these recognized
markers of CV risk.
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